ASX RELEASE (ASX: MDR)

Appendix 3G – Late Lodgment Notice

Please find attached an Appendix 3G (*Notification of issue, conversion, or payment up of unquoted equity securities)*, advising that the following unquoted securities had been issued on 14 February 2023.

No. of Options Issued	Date of Issue	ASX Code
365,000	14 February 2023	MDRAI

MedAdvisor Limited (ASX:MDR) has just become aware that the above options issued to employees were inadvertently overlooked when lodging earlier release. The attached appendix 3G corrects the number of unquoted options on issue.

For the purposes of Listing Rule 3.10.3C, MDR provides the following information:

1. The late lodgement of the Appendix 3G is due to an administrative oversight by the Company. As soon as the oversight was identified, the attached Appendix 3G was lodged with the ASX.

2. MDR confirms that it has reviewed its processes and believes that its disclosure arrangements are adequate and are being enforced and that this was an isolated incident which does not involve any substantive breach of the ASX Listing Rules.

- ENDS -

This announcement has been authorised for release by the Board of MedAdvisor Limited.

About MedAdvisor

MedAdvisor is a world-class medication management platform that empowers patients to more simply manage their medication and improve adherence. MedAdvisor's highly automated and intuitive software system connects patients to tools and education materials from their preferred pharmacy. MedAdvisor works with 32,000 pharmacies in the US to deliver programs to help patients take their medication safely and effectively. In Australia, MedAdvisor has connected over 3.1 million patients through more than 90% of Australian pharmacies. MedAdvisor is on track to become one of the largest players in the global digital adherence market. In 2018 and 2020, MedAdvisor was recognised in the AFR Fast 100. Visit: mymedadvisor.com/investors